Literature DB >> 16274837

Non-alcoholic steatohepatitis: from cell biology to clinical practice.

Helena Cortez-Pinto1, Miguel Carneiro de Moura, Christopher Paul Day.   

Abstract

Entities:  

Mesh：

Year:  2005        PMID： 16274837     DOI： 10.1016/j.jhep.2005.09.002

Source DB:  PubMed          Journal:  J Hepatol        ISSN： 0168-8278            Impact factor:   25.083


× No keyword cloud information.
  61 in total

1.  Focal Fatty liver: more than just a radiographic curiosity?

Authors:  Heather M Patton; Joel E Lavine
Journal:  Gastroenterol Hepatol (N Y)       Date:  2007-03

2.  A chat on fat in liver.

Authors:  Christopher Day; Paul C Adams
Journal:  Can J Gastroenterol       Date:  2006-07       Impact factor: 3.522

3.  N-acetylcysteine attenuates progression of liver pathology in a rat model of nonalcoholic steatohepatitis.

Authors:  January N Baumgardner; Kartik Shankar; Leah Hennings; Emanuele Albano; Thomas M Badger; Martin J J Ronis
Journal:  J Nutr       Date:  2008-10       Impact factor: 4.798

4.  Interleukin-17 exacerbates hepatic steatosis and inflammation in non-alcoholic fatty liver disease.

Authors:  Y Tang; Z Bian; L Zhao; Y Liu; S Liang; Q Wang; X Han; Y Peng; X Chen; L Shen; D Qiu; Z Li; X Ma
Journal:  Clin Exp Immunol       Date:  2011-11       Impact factor: 4.330

Review 5.  Clinical approaches to non-alcoholic fatty liver disease.

Authors:  Katherine J P Schwenger; Johane P Allard
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

Review 6.  Insulin resistance in development and progression of nonalcoholic fatty liver disease.

Authors:  Shahinul Alam; Golam Mustafa; Mahabubul Alam; Nooruddin Ahmad
Journal:  World J Gastrointest Pathophysiol       Date:  2016-05-15

7.  Anthropometric and metabolic characteristics in children with clinically diagnosed nonalcoholic fatty liver disease.

Authors:  Diana R Mager; Simon Ling; Eve A Roberts
Journal:  Paediatr Child Health       Date:  2008-02       Impact factor: 2.253

8.  Prevention of steatosis by hepatic JNK1.

Authors:  Guadalupe Sabio; Julie Cavanagh-Kyros; Hwi Jin Ko; Dae Young Jung; Susan Gray; John Y Jun; Tamera Barrett; Alfonso Mora; Jason K Kim; Roger J Davis
Journal:  Cell Metab       Date:  2009-12       Impact factor: 27.287

9.  Blood F2-isoprostanes are significantly associated with abnormalities of lipid status in rats with steatosis.

Authors:  Man-Jie Zhu; Li-Juan Sun; Yue-Qin Liu; Yan-Ling Feng; Hai-Tao Tong; Ying-He Hu; Zheng Zhao
Journal:  World J Gastroenterol       Date:  2008-08-07       Impact factor: 5.742

Review 10.  Hypertension and hepatic steatosis.

Authors:  Matthew J Brookes; Tariq H Iqbal; Brian T Cooper
Journal:  Curr Hypertens Rep       Date:  2008-06       Impact factor: 5.369
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.